2017 Press Releases

Webcast ImageWebcast
Jefferies Healthcare Conference (Live)
06/06/17 at 12:00 p.m. ET
Jefferies Healthcare Conference
Tuesday, June 6, 2017  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
May 13, 2017Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual MeetingFirst-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat models First to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system in mice showing: approximately 97 percent reduction in serum transthyretin protein levels; 70 percent liver editing efficiency following a single dose; six months post-single-dose durability of stable liver editing WASHINGTON, May 13, 2017 (GLOBE NEWSWIRE) -- Intellia ... Click to view full release
May 02, 2017Intellia Therapeutics Announces First Quarter 2017 Financial ResultsFirst to demonstrate single dose, in vivo results using a proprietary lipid nanoparticle delivery system showing: approximately 97 percent reduction in serum transthyretin protein levels; 70 percent liver editing efficiency following a single dose; six months post-single-dose durability of stable liver editing Appeal of U.S. Patent Trial and Appeal Board decision on CRISPR/Cas9 interference involving Intellia-licensed patent family filed by the University of California and other co-owners ... Click to view full release
April 13, 2017CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board DecisionAppeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reversal of the Patent Trial and Appeals Board’s decision to terminate CRISPR/Cas9 interference In parallel, the companies and their licensors plan to pursue additional patents in the U.S. and worldwide covering the CRISPR/Cas9 technology and its use in cellular and non-cellular settings, including eukaryotic cells BASEL, Switzerland; CAMBRIDGE, Massachusetts; BERKELEY, California; DUBLIN, Ireland, April 13, 20... Click to view full release
April 11, 2017Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology PatentPatent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeutics Patent covers compositions of CRISPR single guide RNA technology for use in non-cellular and cellular settings, including eukaryotic cells CAMBRIDGE, Mass., April 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, announced that the European Patent ... Click to view full release
March 14, 2017Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial ResultsFirst to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levels Further established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic development Executed partnering deal with Regeneron Pharmaceuticals, and continued to advance Intellia’s partnership with Novartis, to support Intellia’s emerging pipeline with six distinct programs in active research and developm... Click to view full release
March 08, 2017Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery TechnologyFirst to demonstrate single dose, in vivo results, showing approximately a 97 percent reduction in serum transthyretin protein levels Durability data show stable liver editing for at least four months Increased liver editing efficiency reported to date at 70 percent, following a single dose CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapies, today... Click to view full release
March 01, 2017Intellia Therapeutics to Present at March Investor Healthcare ConferencesCAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27th Annual Healthcare Conference. ... Click to view full release
February 15, 2017Intellia Therapeutics to Hold Conference Call to Address Patent Interference ProceedingsCAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief executive officer and founder, Jose E. Rivera, executive vice president and general counsel, and Graeme Bell, chief financial officer. To participate on the day of the call, dial 844-882-7840 and use Conference ID#... Click to view full release
February 15, 2017CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells U.S. Patent... Click to view full release
February 01, 2017Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare ConferenceCAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan Bermingham, Ph.D., will present at the Leerink Partners 6th Annual Global Healthcare Conference, Wednesday, February 15, 2017.      Details of the presentation are as follows: Date: Wednesday, February 15, 2017 Loc... Click to view full release
January 11, 2017Intellia Therapeutics Joins Genomics England’s Industry ConsortiumCAMBRIDGE, Mass. and LONDON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium, as the first, dedicated genome editing company to participate in the 100,000 Genomes Project. The GENE Consortium, established in M... Click to view full release